Key result
Prior warfarin with INR <2 linked to ~42% lower death or disability risk vs no anticoagulation.
Why the study?
The study aimed to clarify associations between prior anticoagulation and short- or long-term clinical outcomes in ischemic stroke or TIA patients with nonvalvular atrial fibrillation.
Does prior anticoagulation improve death or disability in ischemic stroke or transient ischemic attack patients with nonvalvular atrial fibrillation?
Population
1189 ischemic stroke or TIA patients with nonvalvular AF hospitalized within 7 days of onset
Comparison
Prior anticoagulation (warfarin with INR <2, INR ≥2, or DOAC) vs no prior anticoagulation
Design
Observational cohort study
Follow-up
2 years
Authors
Loading...
Prior subtherapeutic warfarin was associated with lower 3-month death or disability in AF-related stroke; hypothesis-generating and requires randomized confirmation.
Cohort (n=1,189)
Does prior anticoagulation improve death or disability in ischemic stroke or transient ischemic attack patients with nonvalvular atrial fibrillation?
Effect estimate: OR 0.58 (95% CI 0.42-0.81)
p-value: p=0.001
Prior warfarin treatment in patients with nonvalvular atrial fibrillation experiencing ischemic stroke or TIA is associated with reduced death or disability at 3 months, but not at 2 years.
Tokunaga et al. (2019) conducted a cohort in Ischemic stroke or transient ischemic attack with nonvalvular atrial fibrillation (n=1,189). Prior warfarin treatment vs. No prior anticoagulation was evaluated on Death or disability at 3 months (OR 0.58, 95% CI 0.42-0.81, p=0.001). Prior warfarin treatment with an INR <2 on admission was associated with a lower risk of death or disability at 3 months compared with no prior anticoagulation (OR 0.58; 95% CI 0.42-0.81; P=0.001).